KR20030047907A - 말초 혈관질환, 말초 신경장애, 및 자율 신경장애의 치료방법 - Google Patents

말초 혈관질환, 말초 신경장애, 및 자율 신경장애의 치료방법 Download PDF

Info

Publication number
KR20030047907A
KR20030047907A KR1020027017948A KR20027017948A KR20030047907A KR 20030047907 A KR20030047907 A KR 20030047907A KR 1020027017948 A KR1020027017948 A KR 1020027017948A KR 20027017948 A KR20027017948 A KR 20027017948A KR 20030047907 A KR20030047907 A KR 20030047907A
Authority
KR
South Korea
Prior art keywords
diabetic
peripheral
cgmp pde5
treating
pde5 inhibitor
Prior art date
Application number
KR1020027017948A
Other languages
English (en)
Korean (ko)
Inventor
랄프 이. 우드
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20030047907A publication Critical patent/KR20030047907A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020027017948A 2000-06-30 2001-06-29 말초 혈관질환, 말초 신경장애, 및 자율 신경장애의 치료방법 KR20030047907A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21506500P 2000-06-30 2000-06-30
US60/215,065 2000-06-30
US21902900P 2000-07-18 2000-07-18
US60/219,029 2000-07-18

Publications (1)

Publication Number Publication Date
KR20030047907A true KR20030047907A (ko) 2003-06-18

Family

ID=26909649

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027017948A KR20030047907A (ko) 2000-06-30 2001-06-29 말초 혈관질환, 말초 신경장애, 및 자율 신경장애의 치료방법

Country Status (13)

Country Link
EP (1) EP1303279A1 (ja)
JP (1) JP2004511433A (ja)
KR (1) KR20030047907A (ja)
CN (1) CN1440287A (ja)
AU (1) AU2001279275A1 (ja)
BR (1) BR0112100A (ja)
CA (1) CA2414352A1 (ja)
HU (1) HUP0301451A3 (ja)
IL (1) IL153426A0 (ja)
MX (1) MXPA03000033A (ja)
NZ (1) NZ523108A (ja)
PL (1) PL365565A1 (ja)
WO (1) WO2002002118A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020588D0 (en) * 2000-08-21 2000-10-11 Pfizer Ltd Treatment of wounds
US8133903B2 (en) 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
CA2519357A1 (en) * 2003-03-17 2004-09-30 Pfizer Products Inc. Treatment of type 1 diabetes with pde5 inhibitors
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
EP1838319B1 (en) * 2005-01-07 2018-03-07 The Johns Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
MX2017016930A (es) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders

Also Published As

Publication number Publication date
JP2004511433A (ja) 2004-04-15
WO2002002118A1 (en) 2002-01-10
AU2001279275A1 (en) 2002-01-14
BR0112100A (pt) 2003-05-20
MXPA03000033A (es) 2003-09-25
HUP0301451A3 (en) 2004-10-28
NZ523108A (en) 2005-04-29
HUP0301451A2 (hu) 2003-09-29
PL365565A1 (en) 2005-01-10
IL153426A0 (en) 2003-07-06
CA2414352A1 (en) 2002-01-10
CN1440287A (zh) 2003-09-03
EP1303279A1 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
TWI248816B (en) Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
EP1303304B1 (en) Pharmaceutical combinations for treatment and prevention of diabetes mellitus
CA2587391A1 (en) Compositions useful to treat ocular neovascular diseases and macular degeneration
US6498193B2 (en) Treatment for complications of type 2 diabetes
CN104208654A (zh) 一种以地龙蛋白提取物为主的保健配方
Sahni et al. Recent advances in hyperbaric oxygen therapy
KR20030047907A (ko) 말초 혈관질환, 말초 신경장애, 및 자율 신경장애의 치료방법
RU2543635C2 (ru) Способ и фармацевтические композиции для лечения постпрандиальной гипергликемии диабета ii типа введением через слизистую ротовой полости
EP3701956B1 (en) Prophylactic and/or therapeutic agent for dementia
US20040176387A1 (en) Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
EP1581195B1 (en) Film coated tablet comprising an extract of red vine leaves
AU2002220960A1 (en) Regeneration of blood vessels
WO2002045705A2 (en) Regenaration of blood vessels
CN106902115A (zh) 阿哌沙班在治疗糖尿病足药物中的应用
CN1434710A (zh) 爱滋病特效药
ZA200300015B (en) Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies.
RU2180236C2 (ru) Способ лечения ожогового шока
RU2465896C2 (ru) Фармацевтическая противодиабетическая композиция пролонгированного действия
CA2412213C (en) A method for treating septic shock
JPS6277318A (ja) 熱傷治療剤
Fotiu et al. Antihypertensive efficacy of metolazone
JP2021506983A (ja) 糖尿病性足潰瘍の治療方法
KR20030022352A (ko) 일차성 두통의 치료에서 비타민 혼합물의 용도
JP2005060359A (ja) 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用
JPS5920221A (ja) レイノ−症状の改善・治療剤

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application